Cargando…
Medical Therapy for Heart Failure with Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is a challenging disease state that has long been plagued by heterogeneity in diagnostic criteria and underlying etiologies. Due in part to the complexity of defining this disease and the simplistic approach of only studying medications that hav...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Houston Methodist DeBakey Heart & Vascular Center
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733121/ https://www.ncbi.nlm.nih.gov/pubmed/36561091 http://dx.doi.org/10.14797/mdcvj.1162 |
_version_ | 1784846292341489664 |
---|---|
author | Varnado, Sara Ali, Hyeon-Ju Ryoo Trachtenberg, Barry |
author_facet | Varnado, Sara Ali, Hyeon-Ju Ryoo Trachtenberg, Barry |
author_sort | Varnado, Sara |
collection | PubMed |
description | Heart failure with preserved ejection fraction (HFpEF) is a challenging disease state that has long been plagued by heterogeneity in diagnostic criteria and underlying etiologies. Due in part to the complexity of defining this disease and the simplistic approach of only studying medications that have shown significant improvement in heart failure with reduced ejection fraction, there have been a multitude of negative trials in this population. In the past few years, however, there have been medications that have finally shown to benefit patients with HFpEF. In particular, the blockbuster class of medications called SGLT2 inhibitors have provided a treatment option that improves outcomes in this group of patients. There is increasing focus on HFpEF research that aims to improve the phenotyping of these patients to more successfully tailor therapy and improve patient outcomes. |
format | Online Article Text |
id | pubmed-9733121 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Houston Methodist DeBakey Heart & Vascular Center |
record_format | MEDLINE/PubMed |
spelling | pubmed-97331212022-12-21 Medical Therapy for Heart Failure with Preserved Ejection Fraction Varnado, Sara Ali, Hyeon-Ju Ryoo Trachtenberg, Barry Methodist Debakey Cardiovasc J Review Heart failure with preserved ejection fraction (HFpEF) is a challenging disease state that has long been plagued by heterogeneity in diagnostic criteria and underlying etiologies. Due in part to the complexity of defining this disease and the simplistic approach of only studying medications that have shown significant improvement in heart failure with reduced ejection fraction, there have been a multitude of negative trials in this population. In the past few years, however, there have been medications that have finally shown to benefit patients with HFpEF. In particular, the blockbuster class of medications called SGLT2 inhibitors have provided a treatment option that improves outcomes in this group of patients. There is increasing focus on HFpEF research that aims to improve the phenotyping of these patients to more successfully tailor therapy and improve patient outcomes. Houston Methodist DeBakey Heart & Vascular Center 2022-12-06 /pmc/articles/PMC9733121/ /pubmed/36561091 http://dx.doi.org/10.14797/mdcvj.1162 Text en Copyright: © 2022 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review Varnado, Sara Ali, Hyeon-Ju Ryoo Trachtenberg, Barry Medical Therapy for Heart Failure with Preserved Ejection Fraction |
title | Medical Therapy for Heart Failure with Preserved Ejection Fraction |
title_full | Medical Therapy for Heart Failure with Preserved Ejection Fraction |
title_fullStr | Medical Therapy for Heart Failure with Preserved Ejection Fraction |
title_full_unstemmed | Medical Therapy for Heart Failure with Preserved Ejection Fraction |
title_short | Medical Therapy for Heart Failure with Preserved Ejection Fraction |
title_sort | medical therapy for heart failure with preserved ejection fraction |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733121/ https://www.ncbi.nlm.nih.gov/pubmed/36561091 http://dx.doi.org/10.14797/mdcvj.1162 |
work_keys_str_mv | AT varnadosara medicaltherapyforheartfailurewithpreservedejectionfraction AT alihyeonjuryoo medicaltherapyforheartfailurewithpreservedejectionfraction AT trachtenbergbarry medicaltherapyforheartfailurewithpreservedejectionfraction |